

**Results:** MODS testing of 2932 TB patients determined that 381 (13%) had drug-resistant TB (DRTB; i.e. resistant to isoniazid, rifampicin or both), so 7.7 patients needed to have MODS culture per drug-resistant case identified (16 per MDR case). Drug resistance was more common among re-treatment cases (26%; risk ratio = 1.9,  $P < 0.001$ ; population attributable fraction: 16%). Thus, restricting MODS testing to the 22% of TB patients who were re-treatment cases would only detect 35% of all DRTB (39% of MDR-TB). Additionally among 12 581 contacts, 1335 (11%) had respiratory symptoms, 113 of whom were MODS culture positive (i.e., 0.9% of all contacts and 8.5% of symptomatic contacts). Of these culture-positive contacts 39 (35%) were ZN microscopy-negative. Thus 34 symptomatic household contacts needed to have MODS culture per smear-negative TB case identified.

**Conclusion:** In operational settings, modern diagnostic tests that offer sensitive diagnosis and rapid DRTB testing may provide greatest public health impact when focused on TB patients rather than on enhanced case-finding. These calculations may be adjusted for settings with different rates of smear-negative TB and DRTB.


#### PC-101296-13 A simple colour test for diagnosing MDR-TB and XDR-TB under field conditions

M Tovar,<sup>1,2</sup> S Schumacher,<sup>2</sup> C Osorio,<sup>1</sup> E Ramos,<sup>1</sup> M Llacza,<sup>1</sup> B Herrera,<sup>1</sup> R H Gilman,<sup>1,2,3</sup> C A Evans.<sup>1,4,5</sup> <sup>1</sup>Universidad Peruana Cayetano Heredia, San Martin de Porres, Lima, <sup>2</sup>Asociación Benefica Prisma, San Miguel, Lima, Peru; <sup>3</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; <sup>4</sup>Imperial College London, London, <sup>5</sup>Innovation for Health and Development, London, London, UK.  
e-mail: 03195@upch.edu.pe

**Background:** Increasing rates of drug-resistant and smear-negative TB require improved TB diagnostics that are easy to use, affordable and equipment-minimal. The MDR/XDR-TB Colour Test is a simple, Thin-Layer-Agar-based non-proprietary culture technique that offers concurrent MDR testing and XDR screening. We compared its performance with a standard culture technique.

**Methods:** Sputum samples were collected from patients with suspected TB ( $n = 788$ ). Smear microscopy was done directly from sputum samples, which subsequently underwent culture with the Peruvian standard protocol of modified-Petroff NaOH-decontamination and culture on Ogawa medium. Samples for the Colour Test were collected in parallel directly into sputum pots containing disinfectant that decontaminated the sputum in-transit. Upon arrival in the lab, these were directly applied to selective culture medium without any processing. Positive cultures were indicated by colour change.

**Results:** 265 samples had a culture-positive result and



both Colour Test and Petroff-Ogawa were significantly more sensitive than ZN microscopy (96% and 90% vs. 63%;  $P < 0.0001$ ). The Colour Test also had higher sensitivity than Petroff-Ogawa ( $P = 0.02$ ) and this difference was greatest in the 128 smear-negative samples that were culture-positive (95% vs. 79%;  $P = 0.002$ ). Results were obtained more rapidly in the Colour Test (17 vs. 21 days;  $P < 0.0001$ ) with similar contamination rates (3.5% vs. 2.4%;  $P = 0.2$ ). The Colour Test detected drug-resistant TB in 18% of all culture-positive samples the same day as culture detection with 99% agreement with delayed indirect testing.

**Conclusion:** The Colour Test is a simple culture technique that offers superior characteristics over the current standard culture method. It addresses the rising challenges of paucibacillary disease and drug-resistance while using simple and effective technology that is appropriate to resource-poor settings where these problems are most common.

#### PC-100618-13 Rapid direct MDR-TB testing better predicts clinical outcome than conventional delayed testing

M A Tovar,<sup>1,2</sup> T Valencia,<sup>1</sup> J Alvarado,<sup>1</sup> C Rojas,<sup>1</sup> L Caviedes,<sup>1</sup> S Schumacher,<sup>2</sup> R H Gilman,<sup>1,2,3</sup> C Evans.<sup>1,4,5</sup> <sup>1</sup>Universidad Peruana Cayetano Heredia, San Martin de Porres, Lima, <sup>2</sup>Asociacion Benefica PRISMA, San Miguel, Lima, Peru; <sup>3</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; <sup>4</sup>Imperial College London, London, <sup>5</sup>Innovation for Health and Development, London, UK.  
e-mail: 03195@upch.edu.pe

**Background:** Drug susceptibility testing (DST) is an important tool in the control of multidrug-resistant tuberculosis (MDR-TB). Conventional DST is done indirectly after first culturing the TB strain, thereby delaying the DST result. New DST tests are emerging that culture TB directly on antibiotic-containing media concurrently with drug-free culture. This leads to a much more rapid DST result, which may have an important positive impact on the patient's clinical outcome. Direct and indirect DST may have discrepant results and we therefore investigated the clinical